Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

CervoMed Inc.

NASDAQ: CRVO · Life Sciences · 8 alerts · CIK 1053691

Share price
$1.67Close, Nov 16
Market cap
$25.3M
Shares outstanding
15.13MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All CervoMed Inc. filings on SEC EDGAR ↗

4:08 PM ET 8-K
Financial Results

CervoMed Financial Results

CervoMed reported Q3 2026 financial results and provided updates on its neflamapimod clinical program, including the removal of FDA drug exposure limits and the receipt of an Innovation Passport designation in the UK for dementia with Lewy bodies. The company ended the quarter with $31.1 million in cash and cash equivalents, which is expected to fund operations into late 2025.

Term
Q3 2026

“The Company believes that the neflamapimod clinical development program has been significantly de-risked through the presentation and publication of compelling, supportive datasets throughout this year and the ability to advance the 100mg BID dosing regimen, strengthening its position as a potential therapeutic for dementia with Lewy bodies and other devastating neurodegenerative disorders.”

John Alam, MD, Chief Executive Officer of CervoMed

“As we look ahead to the remainder of the year and into 2027, we believe neflamapimod is well-positioned to succeed in the clinic, drive stockholder value, and ultimately, if approved, bring a transformative therapy to a market with massive, unmet medical needs.”

John Alam, MD, Chief Executive Officer of CervoMed

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.